Koers NurExone Biologic Inc. Toronto S.E.
Aandelen
ENER
CA29278Q1063
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 28,38 mln. 38,8 mln. 26,35 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -5,47 mln. -3,71 mln. | Nettowinst (verlies) 2025 * | -4 mln. -5,47 mln. -3,71 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-4,79
x | K/w-verhouding 2025 * |
-4,79
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 01-04-21 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 15-06-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 03-01-22 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 06-07-23 |
Yoram Drucker
CHM | Chairman | 59 | 01-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+47,30% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |